Jodee A. Kozlak
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Barclays Lifts MGIC Target to $29; AM Best Affirms Ratings. Barclays maintained an Equal-Weight rating on MGIC Investment while raising its price target to $29. In related news, AM Best affirmed the credit ratings of the company's operating subsidiaries. These updates provide a neutral backdrop as the stock trades near its 52-week low, with an average analyst target of $31.20.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Leslie's Announces Chapter 11 Plan for 90% Debt Cut. Leslie's Inc. disclosed a Chapter 11 restructuring plan aimed at reducing debt by 90% and securing $150 million in new capital. This corporate action coincided with a sharp 23% surge in the stock's after-hours trading. The move comes as the stock trades near its 52-week low, reflecting the significant financial restructuring underway.
Transaction History
| KBH | ▲ Buy | Grant | 3,269 | $0 | 4/23/2026 | View on chart |
| MTG | ▲ Buy | Grant | 78 | — | 3/6/2026 | View on chart |
| MTG | ▲ Buy | Grant | 5,077 | — | 2/4/2026 | View on chart |
| MTG | ▲ Buy | Grant | 75 | — | 11/20/2025 | View on chart |
| MTG | ▲ Buy | Grant | 75 | — | 8/21/2025 | View on chart |
| MTG | ▲ Buy | Grant | 67 | — | 5/21/2025 | View on chart |
| KBH | ▲ Buy | Grant | 4,324 | $0 | 4/17/2025 | View on chart |
| MTG | ▲ Buy | Grant | 75 | — | 3/5/2025 | View on chart |
| MTG | ▲ Buy | Grant | 0 | — | 2/14/2025 | View on chart |
| MTG | ▲ Buy | Grant | 4,898 | $125K | 2/5/2025 | View on chart |
| MTG | ▲ Buy | Grant | 79 | — | 11/21/2024 | View on chart |
| MTG | ▲ Buy | Grant | 81 | — | 8/22/2024 | View on chart |
| MTG | ▲ Buy | Grant | 83 | — | 5/21/2024 | View on chart |
| KBH | ▲ Buy | Grant | 3,351 | $0 | 4/18/2024 | View on chart |
| MTG | ▲ Buy | Grant | 86 | — | 3/5/2024 | View on chart |
| MTG | ▲ Buy | Grant | 0 | — | 2/15/2024 | View on chart |
| MTG | ▲ Buy | Grant | 6,310 | $125K | 2/2/2024 | View on chart |
| MTG | ▲ Buy | Grant | 114 | — | 11/28/2023 | View on chart |
| MTG | ▲ Buy | Grant | 57 | — | 8/24/2023 | View on chart |
| MTG | ▲ Buy | Grant | 61 | — | 8/24/2023 | View on chart |
| MTG | ▲ Buy | Grant | 116 | — | 5/25/2023 | View on chart |
| KBH | ▲ Buy | Grant | 4,154 | $0 | 4/20/2023 | View on chart |
| LESL | ▲ Buy | Option Exercise | 6,098 | $0 | 3/15/2023 | View on chart |
| MTG | ▲ Buy | Grant | 125 | — | 3/2/2023 | View on chart |
| MTG | ▲ Buy | Grant | 8,821 | $125K | 2/3/2023 | View on chart |
| MTG | ▲ Buy | Grant | 61 | — | 11/23/2022 | View on chart |
| MTG | ▲ Buy | Grant | 55 | — | 8/25/2022 | View on chart |
| MTG | ▲ Buy | Grant | 49 | — | 5/26/2022 | View on chart |
| KBH | ▲ Buy | Grant | 8,769 | $0 | 4/7/2022 | View on chart |
| LESL | ▲ Buy | Option Exercise | 2,207 | $0 | 3/16/2022 | View on chart |
| MTG | ▲ Buy | Grant | 45 | — | 3/2/2022 | View on chart |
| MTG | ▲ Buy | Grant | 8,085 | $125K | 2/4/2022 | View on chart |
| LESL | ▲ Buy | Option Exercise | 7,353 | $0 | 11/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
KB Home Announces New California Projects, Dividend, and Analyst Sell
KB Home has opened two new California communities, Cypress Ranch and Camellia Glen, adding townhomes priced from $460,000. The company also announced a fourth‑quarter 2026 dividend, adding to its 1.51% yield. Recent analyst coverage includes a sell rating from Melius Research and a fair‑value cut after mixed resets, signaling caution for investors.
KB Home Announces New California Projects, Dividend, and Analyst Sell. KB Home has opened two new California communities, Cypress Ranch and Camellia Glen, adding townhomes priced from $460,000. The company also announced a fourth‑quarter 2026 dividend, adding to its 1.51% yield. Recent analyst coverage includes a sell rating from Melius Research and a fair‑value cut after mixed resets, signaling caution for investors.